Literature DB >> 6510495

Difference of the inhibitory action of verapamil on the positive inotropic effect of Ca2+ between spontaneously hypertensive and normotensive rat myocardium.

N Kondo, S Shibata.   

Abstract

Verapamil, a calcium entry blocker, had a greater inhibitory effect on the positive inotropic effect of excess Ca2+ in SHR than in NWR, suggesting that the cardiac responsiveness to verapamil was enhanced in SHR.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6510495     DOI： 10.1007/bf01951906

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  7 in total

1.  Development of a strain of spontaneously hypertensive rats.

Authors:  K OKAMOTO; K AOKI
Journal:  Jpn Circ J       Date:  1963-03

2.  Calcium kinetics in the aorta of spontaneously hypertensive rats.

Authors:  T T Zsotér; C Wolchinsky; N F Henein; L C Ho
Journal:  Cardiovasc Res       Date:  1977-07       Impact factor: 10.787

3.  Differences of cardiac reactivity between spontaneously hypertensive and normotensive rats.

Authors:  M Fujiwara; M Kuchii; S Shibata
Journal:  Eur J Pharmacol       Date:  1972-07       Impact factor: 4.432

4.  Verapamil and diazoxide antagonism of agonist-induced contractions of aortic strips from normal and spontaneously hypertensive rats (SHR).

Authors:  J V Levy
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1975-07

5.  Comparative dilator effect of verapamil and sodium nitroprusside in forearm arterial bed and dorsal hand veins in man: functional differences between vascular smooth muscle in arterioles and veins.

Authors:  B F Robinson; J G Collier; R J Dobbs
Journal:  Cardiovasc Res       Date:  1979-01       Impact factor: 10.787

6.  Effects of nifedipine on resistance vessels, arteries and veins in man.

Authors:  B F Robinson; R J Dobbs; C R Kelsey
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

7.  Verapamil-induced vasodilation is enhanced in essential hypertension.

Authors:  U L Hulthén; P Bolli; F W Amann; W Kiowski; F R Bühler
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.